Researchers have identified three biomarkers—ARHGEF3, S100A8, and RHOU—that may help diagnose ulcerative colitis (UC) and distinguish it from Crohn's disease. The study analyzed gene expression in patients with UC and healthy controls, finding that these markers were elevated in UC patients.
The diagnostic model combining these biomarkers performed well, with an AUC of 0.991 in the training set and 0.938 and 0.968 in two external validation groups. ARHGEF3 in particular showed significant ability to differentiate UC from Crohn's disease.
This is an observational study, so it shows an association, not cause and effect. The sample size and follow-up were not reported, and limitations were not listed. The results come from multiple datasets and lab experiments, but more research is needed before these biomarkers can be used in clinical practice.
For now, these findings are a step toward more precise diagnosis of UC. Patients should discuss any concerns with their doctor, as these tests are not yet available.